| dc.date.accessioned | 2021-05-12T16:38:46Z | |
| dc.date.available | 2021-05-12T16:38:46Z | |
| dc.date.issued | 2021-04-07 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2603 | |
| dc.description.abstract | The Pan American Health Organization (PAHO) has issued this communiqué in response to the information circulating about potential risks associated with use of the COVID-19 vaccine developed by AstraZeneca and Oxford University, considering the reports of events in European countries. This communiqué offers an overview of the adverse effects following the administration of the Oxford–AstraZeneca COVID-19 vaccine notified in Europe, and of the recommendations issued by the World Health Organization, the European Medicines Agency, and other national regulatory authorities in that respect. In addition, it includes the recommendations of the Pan American Health Organization in consideration of the information and the evidence available. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Infectious Diseases | en_US |
| dc.title | Considerations on Thrombotic Events Following Administration of the AstraZeneca COVID-19 Vaccine in Europe, 7 April 2021 | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Candidate vaccines RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.contributor.corporatename | Pan American Health Organization | en_US |
